Thousands More UK Black Men to Be Invited for Prostate Cancer Screening Trial

The UK government has announced plans to significantly expand a major prostate cancer research trial to include thousands more Black men, a group known to face a higher risk of developing the disease. The move comes as ministers rejected calls for a nationwide prostate cancer screening programme, citing scientific evidence that current testing methods may cause more harm than benefit.

Health Secretary James Murray confirmed that the government had accepted recommendations from the UK National Screening Committee (UKNSC), which advised against introducing population-wide screening using the prostate-specific antigen (PSA) blood test. Experts argue that the PSA test can sometimes lead to unnecessary treatments and anxiety due to false-positive results and overdiagnosis.

Instead, the UKNSC recommended targeted screening for men carrying BRCA2 genetic mutations, which significantly increase the likelihood of developing prostate cancer. Under the proposed programme, men aged 45 to 61 with a BRCA2 mutation and a family history of breast, ovarian, pancreatic, or prostate cancer will be offered PSA testing every two years. The initiative is expected to begin in 2027 and could benefit several thousand men annually.

Prostate cancer remains the most commonly diagnosed cancer among men in the UK, affecting more than 64,000 individuals each year. Research indicates that between 21% and 35% of men carrying a BRCA2 mutation will develop prostate cancer before the age of 80, making them one of the highest-risk groups.

While the screening committee declined to recommend routine testing for Black men, it acknowledged ongoing uncertainty regarding whether the benefits of screening outweigh potential risks in this population. To address this gap in knowledge, the government has pledged £20 million for prostate cancer research and treatment, including funding to expand the Transform trial.

The next phase of the Transform study will specifically recruit Black men aged 45 to 74 across the UK who have not undergone a PSA test or MRI scan within the previous five years. Researchers hope the expanded participation will provide valuable evidence about the most effective ways to detect prostate cancer in higher-risk communities.

The decision has sparked criticism from campaigners and patient advocates. Nick Jones, founder of Soho House and a prostate cancer survivor, accused the government of failing to address inequalities in cancer detection and treatment.

He argued that the current approach maintains an outdated system and ignores concerns raised by campaigners and community representatives who have sought greater engagement with policymakers. According to Jones, delaying broader screening measures could result in preventable deaths.

Deputy Prime Minister David Lammy voiced strong support for expanding research among Black men, describing the issue as deeply personal. Lammy revealed that two of his brothers have been diagnosed with prostate cancer and emphasized the importance of reducing health inequalities and improving outcomes for those at greatest risk.

Cancer Research UK supported the government's decision, noting that scientific evidence remains divided over the effectiveness of widespread PSA testing. The charity acknowledged that some patients and advocacy groups may be disappointed but said policy decisions should continue to be guided by robust clinical evidence.

The expanded Transform trial is expected to play a crucial role in shaping future prostate cancer screening policies and determining whether targeted testing could help save more lives among high-risk groups.